CTXR · Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. executed a registered direct offering and concurrent private placement to raise capital for its ongoing operations, specifically targeting the commercialization of LYMPHIR™. The financing structure involved the sale of 4,730,457 shares of common stock and pre-funded warrants for 345,686 shares, priced effectively at-the-market under Nasdaq rules. The offering generated gross proceeds of approximately $5.0 million, with net proceeds expected to be $4.5 million after deducting placement agent fees and offering expenses. H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 7.0% cash fee and warrants to purchase 355,330 shares as compensation. The transaction included a 45-day lock-up period restricting the Company from issuing additional securities. The common warrants issued in the private placement carry an exercise price of $0.86 and are exercisable for five years. This capital injection is critical for supporting the company's strategic initiatives, including the commercial launch of LYMPHIR™ and funding development programs for other product candidates like Mino-Lok® and CITI-002.